Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 146

Sort by

Sort Order Select

Journal Articles

RIT1 mutations in myeloid neoplasms

Lukas Ronner, Guang Yang, David Lieberman, Daria Babushok

Blood (2025) 146 (Supplement 1): 5628.

https://doi.org/10.1182/blood-2025-5628

Published: 2025

Journal Articles

Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study

Andreas Reiter, Tracy George, Deepti Radia, Michael Deininger, Johannes Luebke, Hui-Min Lin, Ilda Bidollari, Joana Caetano-Lopes, Guang Yang, Amber King, Saša Dimitrijević, Daniel Deangelo, Jason Gotlib

Blood (2025) 146 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2025-1022

Published: 2025

Journal Articles

Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study

Mariana Castells, Vishnu Sundaresh, Jason Gotlib, Tsewang Tashi, Vito Sabato, Cristina Bulai Livideanu, Cem Akin, Deepti Radia, Frank Siebenhaar, Daniel Deangelo, Tracy George, Hui-Min Lin, Janet Hong, Ashley Doyle, Guang Yang, Rachel Erlich, Kate Newberry, Benjamin Lampson, Ivan Alvarez-Twose

Blood (2025) 146 (Supplement 1): 5582.

https://doi.org/10.1182/blood-2025-5582

Published: 2025

Journal Articles

An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study

Jens Panse, Tsewang Tashi, Jason Gotlib, Mariana Castells, Ivan Alvarez-Twose, Cem Akin, Cristina Bulai Livideanu, Vito Sabato, Juliana Schwaab, Andreas Reiter, Sigurd Broesby-Olsen, Frank Siebenhaar, Hui-Min Lin, Janet Hong, Benjamin Lampson, Guang Yang, Tracy George, Deepti Radia

Blood (2025) 146 (Supplement 1): 5573.

https://doi.org/10.1182/blood-2025-5573

Published: 2025

Journal Articles

Blood-Based Proteomics for Deeper Insights into Indolent Systemic Mastocytosis: The Pioneer Trial Experience

Hussein A. Abbas, Annie Nguyen, Bofei Wang, Min Chen, Guang Yang, Ben Lampson, Rachel L. Erlich, Ivo Veletic

Blood (2024) 144 (Supplement 1): 6569.

https://doi.org/10.1182/blood-2024-205556

Published: 2024

Journal Articles

Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Deepti H. Radia, Tsewang Tashi, Ivan Alvarez-Twose, Patrizia Bonadonna, Hanneke Oude Elberink, Sonia Cerquozzi, Tracy I. George, Guang Yang, Mark Rosenzweig, Hui-Min Lin, Ben Lampson, Rachel L. Erlich, Jason Gotlib

Blood (2024) 144 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2024-207798

Published: 2024

Journal Articles

Establishment of a Novel Waldenström's Macroglobulinemia (WM) Cell Line Bcwm.2 with Del6q and Unique MYD88 S243N , LYN I297N , SPI1 Q227E Mutations and That Shows Robust In Vivo Engraftment in SCID NOD Mice

Shirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, Amanda Kofides, Kara M Soroko, Johany Penailillo, Alexa G Canning, Yang Cao, Guang Yang, Lian Xu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Ruben D. Carrasco, Prafulla C. Gokhale, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2024-211381

Published: 2024

Journal Articles

DNA Damage Response Constrains Cell Growth and Drives Clonal Hematopoiesis in Telomere Biology Disorders

Blood (2023) 142 (Supplement 1): 1356.

https://doi.org/10.1182/blood-2023-173666

Published: 2023

Journal Articles

Picalm::MLLT10 can Identify a New Subgroup of Acute Leukemias of Ambiguous Lineage with Unique Extramedullary Disease and Treatment Response

Haimin Sun, Yongmei Zhu, Jianfeng Li, Lingling Zhao, Guang Yang, Zeying Yan, Ying Wang, Zhiyin Liu, Ran An, Sujiang Zhang

Blood (2023) 142 (Supplement 1): 6078.

https://doi.org/10.1182/blood-2023-172604

Published: 2023

Journal Articles

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

Blood (2022) 140 (Supplement 1): 1740–1741.

https://doi.org/10.1182/blood-2022-170412

Published: 2022

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Blood (2021) 138 (20): 1966–1979.

https://doi.org/10.1182/blood.2021011405

Published: 2021

Includes: Supplemental data

Journal Articles

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Maria Luisa Guerrera, Guang Yang, Xia Liu, Nickolas Tsakmaklis, Maria G Demos, Amanda Kofides, Manit Munshi, Lian Xu, Christopher J Patterson, Jorge J. Castillo, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Joshua Gustine, Tomasz Sewastianik, Ruben D. Carrasco, Steven P Treon, Zachary R Hunter

Blood (2021) 138 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2021-154160

Published: 2021

Journal Articles

Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study

Michael W. Deininger, Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, Guang Yang, Jayita Sen, Hui-Min Lin, Brenton Mar, Jason Gotlib

Blood (2021) 138 (Supplement 1): 318.

https://doi.org/10.1182/blood-2021-150872

Published: 2021

Journal Articles

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Joshua Gustine, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Timothy P White, Carly Leventoff, Christopher J Patterson, Andrew R. Branagan, Prafulla Gokhale, Michael J Poitras, Zachary R Hunter, Maria Luisa Guerrera, Jorge J. Castillo, Guang Yang, Steven P Treon

Blood (2021) 138 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2021-153856

Published: 2021

Journal Articles

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

Blood (2021) 138 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2021-153610

Published: 2021

Journal Articles

Post-Transplant Blockade of CXCR4 Improves Complete Remission Rates and Donor Stem Cell Engraftment without Aggravating Gvhd

Long Su, Ming Hui Fang, Jun Zou, Su Jun Gao, Xiao Yi Gu, Xian Di Meng, Xue Wang, Zheng Hu, Yong Guang Yang

Blood (2021) 138 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2021-149434

Published: 2021

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

Journal Articles

Giant bizarre melanoma cells mimicking megakaryocytes

Christopher M. Sande, Guang Yang

Blood (2021) 137 (4): 576.

https://doi.org/10.1182/blood.2020007341

Published: 2021

Journal Articles

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon, Jorge J. Castillo, Alan P. Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang

Blood (2020) 135 (21): 1912–1915.

https://doi.org/10.1182/blood.2020006288

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

RIT1 mutations in myeloid neoplasms

Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study

Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study

An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study

Blood-Based Proteomics for Deeper Insights into Indolent Systemic Mastocytosis: The Pioneer Trial Experience

Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Establishment of a Novel Waldenström's Macroglobulinemia (WM) Cell Line Bcwm.2 with Del6q and Unique MYD88 S243N , LYN I297N , SPI1 Q227E Mutations and That Shows Robust In Vivo Engraftment in SCID NOD Mice

DNA Damage Response Constrains Cell Growth and Drives Clonal Hematopoiesis in Telomere Biology Disorders

Picalm::MLLT10 can Identify a New Subgroup of Acute Leukemias of Ambiguous Lineage with Unique Extramedullary Disease and Treatment Response

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

Post-Transplant Blockade of CXCR4 Improves Complete Remission Rates and Donor Stem Cell Engraftment without Aggravating Gvhd

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Giant bizarre melanoma cells mimicking megakaryocytes

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only